reports
Wuxi Biologics (Cayman) Inc: 1 director
A director at Wuxi Biologics (Cayman) Inc bought 831,000 shares at 13.881HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
- Dominic Rose
- Naresh Chouhan
Global CDMO's - Quantifying the Aducanumab Windfall (20 pgs)
Whilst most people consider the US election outcome as the most important event this week, for millions of Alzheimer’s (AD) patients & their families, the Aducanumab FDA AdCom on Friday is likely to be more impactful. Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact of a potential AD windfall from Biogen’s aducanumab. We believe Biogen will already have a shortlist of CDMO suppliers as we show they can only produce ~25% of the quantity required & the FDA will ...
- Carol Dou Xiao Qin
- Desmond Chong Chee Wai
- Jacquelyn Yow Hui Li
- Jayson Kong
- Jie Ying Chloe Tan
- Jonathan Koh
- K Ajith
- Ken Lee
- Leow Huey Chuen
- Loke Pei Hao
- Philip Wong
- Tanadech Rungsrithananon
Regional Morning Notes - Wednesday, October 21, 2020
GREATER CHINA Results China Yongda Automobile Services Holdings (3669 HK/BUY/HK$11.12/Target: HK$15.00): 3Q20: Net profit up 41% yoy, beating estimates; raise target price to HK$15.00. Update Cathay Pacific Airways (293 HK/BUY/HK$5.72/Target: HK$6.70): Time to add positions as travel bubbles form and CX restructures; Upgrade to BUY. The United Laboratories International Holdings: (3933 HK/BUY/HK$7.16/Target: HK$9.75): Continues with solid business expansion; targeting to secure a 15-20% insulin ...
- Carol Dou Xiao Qin
WuXi Biologics (Cayman) Inc (2269 HK) : Win-the-molecule strategy supp...
Amid the COVID-19 pandemic, WuXi Bio has adopted a business strategy of win-themolecule, which has allowed the company to successfully attract an increasing number of new integrated projects from customers and competitors. It has added 72 projects to its pipeline ytd. Management has guided for accelerated revenue growth of 40% yoy in 2H20 and over 50% yoy in 2021. Maintain BUY and raise target price to HK$252.00.
- Carol Dou Xiao Qin
- Jayson Kong
- Joyce Chan Pui Lai
- K Ajith
- Ken Lee
Greater China Daily: Wednesday, October 21, 2020
KEY HIGHLIGHTS Results China Yongda Automobile Services Holdings (3669 HK/BUY/HK$11.12/Target: HK$15.00) 3Q20: Net profit up 41% yoy, beating estimates; raise target price to HK$15.00. Update Cathay Pacific Airways (293 HK/BUY/HK$5.72/Target: HK$6.70) Time to add positions as travel bubbles form and CX restructures; Upgrade to BUY. The United Laboratories International Holdings (3933 HK/BUY/HK$7.16/Target: HK$9.75) Continues with solid business expansion; targeting to secure a 15-20% insuli...
- Carol Dou Xiao Qin
- Michael Cheung Ho Bun
WuXi Biologics (Cayman) (2269 HK) : 1H20: Adjusted net profit up 40.7%...
WuXi Bio reported robust results with revenue and adjusted net profit soaring 21.0% yoy and 40.7% yoy respectively in 1H20. Earnings growth came in higher than our previous forecast of 31.7% yoy for 2020. We believe the company will deliver even stronger revenue and earnings growth in 2H20, given its perseverance in its global expansion amid the pandemic and surging backlog. Upgraded to BUY with a higher target price of HK$200.00.
- Carol Dou Xiao Qin
- Chong Lee Len
- Desmond Chong Chee Wai
- Jie Ying Chloe Tan
- John Cheong Ming Chern
- Johnny Yum Chung Man
- Julia Pan Mengyao
- Kader Farhan Bin Kader Ridzwan
- Ken Lee
- Kong Ho Meng
- Kowit Pongwinyoo
- Kwanchai Atiphophai
- Llelleythan Tan Tan
- Michael Cheung Ho Bun
- Neo Chen Wentao
- Peerawat Dentananan
- Raphon Prima
- Sandra Huang Jieqiong
- Thunya Sutavepramochanon
Regional Morning Notes - Wednesday, August 19, 2020
GREATER CHINA Sector Machinery: 1H20 results preview: Robust results and favourable 2H20 in sight. Results Kingsoft Corp (3888 HK/BUY/HK$39.65/Target: HK$53.00): 2Q20: Top-line surges on blockbuster game, WPS outlook brighter. Maintain BUY. Nexteer (1316 HK/BUY/HK$5.25/Target: HK$7.50): 1H20: Results in line; recovery expected from 2H20. Sany Heavy Equipment International Holdings (631 HK/BUY/HK$4.15/Target: HK$5.50): 1H20: Results in line; improvements across the board on track. Shenzhen Inovan...
BBNI PT BANK NEGARA INDONESIA (PERSERO) TBK CLASS B
ERW ERAWAN GROUP
STA SRI TRANG AGRO-INDUSTRY PCL
SXC SUNNY OPTICAL TECHNOLOGY (GROUP) CO. LTD.
3K1 KINGSOFT CORP. LTD.
300124 SHENZHEN INOVANCE TECHNOLOGY CO. LTD CLASS A
BDMS-R BANGKOK DUSIT MEDICAL SERVICES PCL NVDR
SAWAD SRISAWAD CORPORATION PUBLIC COMPANY LTD
2269 WUXI BIOLOGICS (CAYMAN) INC.
MLK MALAKOFF CORP BHD
SCGB SUNWAY CONSTRUCTION GROUP BH
DLG DIALOG GROUP BHD
PMAH PRESS METAL ALUMINIUM HOLDIN
1316 NEXTEER AUTOMOTIVE GROUP LTD
631 SANY HEAVY EQUIPMENT INTERNATIONAL HOLDINGS CO LTD
- Carol Dou Xiao Qin
- Johnny Yum Chung Man
- Joyce Chan Pui Lai
- Julia Pan Mengyao
- Ken Lee
- Michael Cheung Ho Bun
- Neo Chen Wentao
- Sandra Huang Jieqiong
Greater China Daily: Wednesday, August 19, 2020
KEY HIGHLIGHTS Sector Machinery 1H20 results preview: Robust results and favourable 2H20 in sight. Results Kingsoft Corp (3888 HK/BUY/HK$39.65/Target: HK$53.00) 2Q20: Top-line surges on blockbuster game, WPS outlook brighter. Maintain BUY. Nexteer (1316 HK/BUY/HK$5.25/Target: HK$7.50) 1H20: Results in line; recovery expected from 2H20. Sany Heavy Equipment International Holdings (631 HK/BUY/HK$4.15/Target: HK$5.50) 1H20: Results in line; improvements across the board on track. Shenzhen I...
- Carol Dou Xiao Qin
- Michael Cheung Ho Bun
Wuxi Biologics Cayman Inc : Turning challenges into opportunitie.
The Covid-19 pandemic caused delays in revenue booking in 1H20, but boosted services demand for WuXi Bio. By winning more new customers and integrated projects, the company will turn challenges into opportunities. Moreover, WuXi Bio is expanding service capacity and investing in next-generation technologies to deliver sustainable high growth and improve its global market share during the pandemic. Maintain BUY and target price of HK$170.00.
- Benyamin Mikael
- Carol Dou Xiao Qin
- Clement Ho Jia Xing
- K Ajith
- Kader Farhan Bin Kader Ridzwan
- Malaysia Research Team
- Michael Cheung Ho Bun
- Tanadech Rungsrithananon
- Thunya Sutavepramochanon
Regional Morning Notes - Monday, June 22, 2020
GREATER CHINA Update WuXi Biologics (Cayman) Inc (2269 HK/BUY/HK$138.60/Target: HK$170.00): Turning challenges into opportunities. INDONESIA Update Pratama Widya (PTPW IJ/NOT RATED/Rp905): Highest margin in the construction sector with exposure to high-speed railway. MALAYSIA Sector REITs: Retail- and hospitality-centric REITs were the hardest hit by Covid-19, while offices were relatively resilient. MQREIT is our top pick for the sector. Results UEM Sunrise (UEMS MK/HOLD/RM0.45/Target: RM0.48...
- Carol Dou Xiao Qin
- Joyce Chan Pui Lai
- Michael Cheung Ho Bun
Greater China Daily: Monday, June 22, 2020
KEY HIGHLIGHTS Update WuXi Biologics (Cayman) Inc (2269 HK/BUY/HK$138.60/Target: HK$170.00) Turning challenges into opportunities. TRADERS’ CORNER AAC Tech (2018 HK): Trading Buy Range: HK$47.25-47.30 Zhongsheng Group (881 HK): Trading Buy Range: HK$42.50-42.55
- Carol Dou Xiao Qin
- Michael Cheung Ho Bun
WuXi Biologics (Cayman) - A fruitful 2020 despite COVID-19 outbreak
The COVID-19 pandemic has boosted biologics service demand. WuXi Bio has clinched 15 COVID-19 related projects in the past few months, which will ensure a fruitful 2020 for the company. Also, continuous expansion of service capabilities and capacities will enable WuXi Bio to attract an increasing number of projects and generate sustainable growth in the long term. Maintain BUY and target price of HK$170.00.
- Carol Dou Xiao Qin
- Jacquelyn Yow Hui Li
- John Cheong Ming Chern
- Jonathan Koh
- Leow Huey Chuen
- Llelleythan Tan Tan
- Lucas Teng Yao Yang
- Michael Cheung Ho Bun
- Nick Liu Sunliang
- Nicola Ho Fang Lin
- Raphon Prima
- Shaun Tan
- Thunya Sutavepramochanon
- Ziv Ang Sze Champ
Regional Morning Notes - Tuesday, May 26, 2020
GREATER CHINA Sector CRO/CDMO: The fast movers in innovation excellence. Property: Policy interpretation: Investment opportunities still exist in the property industry. Initiate Coverage Frontage Holdings Corporation (1521 HK/BUY/HK$4.13/Target: HK$5.00): Growing service offerings for a strong take-off. WuXi AppTec (2359 HK/BUY/HK$114.50/Target: HK$145.20): Ready to fly higher. Update WuXi Biologics (Cayman) Inc (2269 HK/BUY/HK$126.50/Target: HK$170.00): A fruitful 2020 despite COVID-19 outbrea...
- Carol Dou Xiao Qin
- Michael Cheung Ho Bun
CRO/CDMO - The fast movers in innovation excellence
The CRO/CDMO is one of the fastest-growing sectors in the pharmaceutical industry and is projected to expand at a 12.9% CAGR globally and 28.5% in China over 2019-24. Capturing new business opportunities offered by growing pharmaceutical R&D investment, China’s CRO/CDMO players, such as WuXi AppTec, WuXi Bio and Frontage, have actively expanded their service offerings and capacities and aim to become global leaders in the next 5-10 years. Initiate coverage with OVERWEIGHT.
- Carol Dou Xiao Qin
- Joyce Chan Pui Lai
- Michael Cheung Ho Bun
- Nick Liu Sunliang
- Shaun Tan
- Ziv Ang Sze Champ
Greater China Daily: Tuesday, May 26, 2020
KEY HIGHLIGHTS Sector CRO/CDMO The fast movers in innovation excellence. Property Policy interpretation: Investment opportunities still exist in the property industry. Initiate Coverage Frontage Holdings Corporation (1521 HK/BUY/HK$4.13/Target: HK$5.00) Growing service offerings for a strong take-off. WuXi AppTec (2359 HK/BUY/HK$114.50/Target: HK$145.20) Ready to fly higher. Update WuXi Biologics (Cayman) Inc (2269 HK/BUY/HK$126.50/Target: HK$170.00) A fruitful 2020 despite COVID-19 ...
- Carol Dou Xiao Qin
- Michael Cheung Ho Bun
China CRO/CDMO: The fast movers in innovation excellence. OVERWEIGHT
CRO/CDMO is one of the fastest-growing sectors in the pharmaceutical industry, projected to expand at a 12.9% CAGR globally and 28.5% in China over 2019-24. Capturing the new business opportunities offered by growing pharmaceutical R&D investment, China’s CRO/CDMO players, such as WuXi AppTec, WuXi Bio and Frontage, have actively expanded their service offerings and capacities and aim to become global leaders in the next 5-10 years. Initiate coverage on the sector with OVERWEIGHT.
- Carol Dou Xiao Qin
- Michael Cheung Ho Bun
Healthcare - Fear not of GPO, focus on innovation
Facing continued GPO price pressure on generics, pharmaceutical and medical device producers have increasingly invested in new product R&D. CRO/CDMO service providers are the key beneficiaries. Companies with strong R&D capabilities and strong pipelines will continue to outperform. Maintain OVERWEIGHT on the healthcare sector. Our top picks are WuXi Bio (2269HK) and Mindray (300760CH).
WUXI BIO reduced its risk exposure resulting in an upgrade to Slightly...
WUXI BIO (HK), a company active in the Pharmaceuticals industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date April 17, 2020, the closing price was HKD 11...
- Carol Dou Xiao Qin
- Michael Cheung Ho Bun
Healthcare - 2019 results review: Mostly in line; mixed impact from CO...
Healthcare companies reported 2019 results that were mostly in line with our estimates. CRO and medical devices companies reported strong growth in 2019, while drug producers and distributors saw mixed impact from the GPO policy. The COVID-19 outbreak brought significant business disruption in 1H20 and we believe the healthcare sector will post slower yoy growth in 2020. CRO and medical equipment leaders, Mindray and WuXi Bio, will continue to outperform. Maintain OVERWEIGHT on the sector.
01177 SINO BIOPHARMACEUTICAL LIMITED
X2S SINOPHARM GROUP CO. LTD. CLASS H
853 MICROPORT SCIENTIFIC CORP
2269 WUXI BIOLOGICS (CAYMAN) INC.
1558 YICHANG HEC CHANGJIANG PHA-H
1066 SHANDONG WEIGAO GP MEDICAL-H
3933 THE UNITED LABORATORIES INTE
570 CHINA TRADITIONAL CHINESE ME
2877 CHINA SHINEWAY PHARMACEUTICA
2633 JACOBSON PHARMA CORP LTD
300760 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO. LTD. CLASS A
- Carol Dou Xiao Qin
- Eric Wang Zhen
- Jacquelyn Yow Hui Li
- Jayson Kong
- K Ajith
- Keith Wee Teck Keong
- Kwanchai Atiphophai
- Lee Yuk Kei
- Leow Huey Chuen
- Malaysia Research Team
- Michael Cheung Ho Bun
- Neo Chen Wentao
- Nick Liu Sunliang
- Sandra Huang Jieqiong
- Shaun Tan
- Stevanus Juanda
- Tanadech Rungsrithananon
- Vanness Wong Wan
- Vincent Khoo Boo Aik
- Zhifeng Shen
- Ziv Ang Sze Champ
Regional Morning Notes - Monday, March 30, 2020
GREATER CHINA Results China Resources Cement (1313 HK/BUY/HK$8.79/Target: HK$10.39): 2019: Rock-solid fundamentals; upgrade to BUY. China Shenhua Energy (1088 HK/BUY/HK$14.36/Target: HK$19.02): 2019: Higher dividends for 2019-21; upgrade to BUY. CIFI Holdings (884 HK/BUY/HK$5.40/Target: HK$7.13): 2019: Steady sales growth. CMGE Technology Group (302 HK/BUY/HK$2.74/Target: HK$4.54): 2019: Earnings above estimates; rich gaming pipeline and rosy outlook in 2020. CR Gas (1193 HK/HOLD/HK$41.80/Targe...
F34 WILMAR INTERNATIONAL LIMITED
601398 INDUSTRIAL AND COMMERCIAL BANK OF CHINA LIMITED CLASS A
601088 CHINA SHENHUA ENERGY CO. LTD. CLASS A
00884 CIFI HOLDINGS (GROUP) CO. LTD.
C6L SINGAPORE AIRLINES LTD.
2269 WUXI BIOLOGICS (CAYMAN) INC.
§3§3 CHINA RESOURCES CEMENT
STMB SYARIKAT TAKAFUL MALAYSIA
KIML KIM LOONG RESOURCES BHD
ICBP INDOFOOD CBP SUKSES MAKMUR T
302 CMGE TECHNOLOGY GROUP LTD
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.